1. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.
- Author
-
Bernaudin F, Souillet G, Vannier JP, Plouvier E, Lemerle S, Michel G, Bordigoni P, Lutz P, and Kuentz M
- Subjects
- Adolescent, Africa ethnology, Anemia, Sickle Cell mortality, Bone Marrow Purging adverse effects, Bone Marrow Purging methods, Busulfan adverse effects, Child, Child, Preschool, Cyclophosphamide adverse effects, Cystitis chemically induced, Female, France epidemiology, Graft Survival, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology, Hemorrhage chemically induced, Humans, Immunosuppressive Agents adverse effects, Male, Treatment Outcome, West Indies ethnology, Anemia, Sickle Cell therapy, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation mortality
- Abstract
Fourteen S/S children with severe SCD were transplanted with marrow from HLA identical siblings. All developed frequent (> 4/y) vasoocclusive crises (VOC) and recurrent acute chest syndrome episodes (n:10), osteitis (n:3), osteonecrosis (n:3), strokes (n:3) or frequent massive deglobulisation (n:2). Two children undergone splenectomy, 2 were chelated and 2 had erythroid allo-immunization. Ethnic origins were from various countries in Africa (n:10), North-Africa (n:3) or West Indies (n:1). At BMT, they were 2y 3m to 14y 9m old (mean:8y 7m). Donors were AS (n:11) or AA (n:3). At first, various conditioning regimens were used consisting of busulfan (BU) plus Cyclophosphamide (CY) at different doses: CY:200 mg/kg (n:12) or 260 mg/kg (n:2); BU:14 mg/kg (n:1), 16 mg/kg (n:9), > 16 mg/kg (n:4); 1 patient received also TLI and one other antithymoglobulin (ATG): 20 mg/kg. GVHD prophylaxis was CSA alone (n:4) or CSA plus short-term MTX (n:10). Median follow-up was 23 months (8 m. to 48 m.). All patients had an engraftment (d13 to d32) with a stable total chimerism in 10/14 patients who are cured. In the 4 others, partial chimerism was observed: one patient had a early and progressive rejection of his graft but is doing very well (28 m. follow-up) without any manifestation of SCD, with a high stable 22% Hb F level. One patient developed an aplastic anaemia 15 m after BMT: a second BMT was achieved 21 m after the first one with engraftment and total chimerism. Two patients have a relatively stable partial chimerism with still undergoing CSA therapy (11 m. and 23 m. follow-up).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1993